nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—Emotional distress—Metformin—polycystic ovary syndrome	0.012	0.0519	CcSEcCtD
Paroxetine—Appetite absent—Metformin—polycystic ovary syndrome	0.0102	0.0444	CcSEcCtD
Paroxetine—Hypothermia—Metformin—polycystic ovary syndrome	0.00908	0.0394	CcSEcCtD
Paroxetine—Body temperature decreased—Metformin—polycystic ovary syndrome	0.00908	0.0394	CcSEcCtD
Paroxetine—Toothache—Metformin—polycystic ovary syndrome	0.00837	0.0363	CcSEcCtD
Paroxetine—CYP2C9—urine—polycystic ovary syndrome	0.00732	0.0931	CbGeAlD
Paroxetine—HTR2A—urine—polycystic ovary syndrome	0.00603	0.0767	CbGeAlD
Paroxetine—CYP2D6—urine—polycystic ovary syndrome	0.00549	0.0698	CbGeAlD
Paroxetine—TACR1—adipose tissue—polycystic ovary syndrome	0.00527	0.067	CbGeAlD
Paroxetine—Neuropathy—Metformin—polycystic ovary syndrome	0.00478	0.0207	CcSEcCtD
Paroxetine—TACR1—adrenal gland—polycystic ovary syndrome	0.00473	0.0601	CbGeAlD
Paroxetine—Lightheadedness—Metformin—polycystic ovary syndrome	0.00455	0.0198	CcSEcCtD
Paroxetine—Ear pain—Metformin—polycystic ovary syndrome	0.00433	0.0188	CcSEcCtD
Paroxetine—TACR1—endocrine gland—polycystic ovary syndrome	0.0041	0.0521	CbGeAlD
Paroxetine—Injury—Metformin—polycystic ovary syndrome	0.00402	0.0174	CcSEcCtD
Paroxetine—Renal impairment—Metformin—polycystic ovary syndrome	0.00388	0.0168	CcSEcCtD
Paroxetine—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00379	0.0164	CcSEcCtD
Paroxetine—Lethargy—Metformin—polycystic ovary syndrome	0.00377	0.0164	CcSEcCtD
Paroxetine—Migraine—Metformin—polycystic ovary syndrome	0.00364	0.0158	CcSEcCtD
Paroxetine—Dehydration—Metformin—polycystic ovary syndrome	0.00344	0.0149	CcSEcCtD
Paroxetine—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.00341	0.0148	CcSEcCtD
Paroxetine—Breast disorder—Metformin—polycystic ovary syndrome	0.00334	0.0145	CcSEcCtD
Paroxetine—Cramp muscle—Metformin—polycystic ovary syndrome	0.00333	0.0144	CcSEcCtD
Paroxetine—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.0033	0.0143	CcSEcCtD
Paroxetine—Influenza—Metformin—polycystic ovary syndrome	0.00319	0.0139	CcSEcCtD
Paroxetine—Pancreatitis—Metformin—polycystic ovary syndrome	0.00313	0.0136	CcSEcCtD
Paroxetine—Angina pectoris—Metformin—polycystic ovary syndrome	0.00311	0.0135	CcSEcCtD
Paroxetine—Sweating increased—Metformin—polycystic ovary syndrome	0.00311	0.0135	CcSEcCtD
Paroxetine—Drowsiness—Metformin—polycystic ovary syndrome	0.00285	0.0123	CcSEcCtD
Paroxetine—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.00279	0.0121	CcSEcCtD
Paroxetine—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00269	0.0117	CcSEcCtD
Paroxetine—Bradycardia—Metformin—polycystic ovary syndrome	0.0026	0.0113	CcSEcCtD
Paroxetine—Rhinitis—Metformin—polycystic ovary syndrome	0.00256	0.0111	CcSEcCtD
Paroxetine—Hepatitis—Metformin—polycystic ovary syndrome	0.00256	0.0111	CcSEcCtD
Paroxetine—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00254	0.011	CcSEcCtD
Paroxetine—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00252	0.0109	CcSEcCtD
Paroxetine—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00251	0.0109	CcSEcCtD
Paroxetine—Eye disorder—Metformin—polycystic ovary syndrome	0.00239	0.0104	CcSEcCtD
Paroxetine—Flushing—Metformin—polycystic ovary syndrome	0.00237	0.0103	CcSEcCtD
Paroxetine—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00237	0.0103	CcSEcCtD
Paroxetine—Angiopathy—Metformin—polycystic ovary syndrome	0.00232	0.0101	CcSEcCtD
Paroxetine—Immune system disorder—Metformin—polycystic ovary syndrome	0.00231	0.01	CcSEcCtD
Paroxetine—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.0023	0.00999	CcSEcCtD
Paroxetine—Chills—Metformin—polycystic ovary syndrome	0.00229	0.00995	CcSEcCtD
Paroxetine—Malnutrition—Metformin—polycystic ovary syndrome	0.00223	0.00965	CcSEcCtD
Paroxetine—Erythema—Metformin—polycystic ovary syndrome	0.00223	0.00965	CcSEcCtD
Paroxetine—Flatulence—Metformin—polycystic ovary syndrome	0.00219	0.00951	CcSEcCtD
Paroxetine—Dysgeusia—Metformin—polycystic ovary syndrome	0.00218	0.00945	CcSEcCtD
Paroxetine—CHRM3—adipose tissue—polycystic ovary syndrome	0.00216	0.0275	CbGeAlD
Paroxetine—Muscle spasms—Metformin—polycystic ovary syndrome	0.00214	0.00928	CcSEcCtD
Paroxetine—Vision blurred—Metformin—polycystic ovary syndrome	0.0021	0.0091	CcSEcCtD
Paroxetine—Tremor—Metformin—polycystic ovary syndrome	0.00208	0.00904	CcSEcCtD
Paroxetine—CHRM2—endocrine gland—polycystic ovary syndrome	0.00207	0.0263	CbGeAlD
Paroxetine—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.00206	0.00895	CcSEcCtD
Paroxetine—Malaise—Metformin—polycystic ovary syndrome	0.00201	0.0087	CcSEcCtD
Paroxetine—Syncope—Metformin—polycystic ovary syndrome	0.002	0.00865	CcSEcCtD
Paroxetine—Palpitations—Metformin—polycystic ovary syndrome	0.00197	0.00853	CcSEcCtD
Paroxetine—CYP2B6—adrenal cortex—polycystic ovary syndrome	0.00196	0.0249	CbGeAlD
Paroxetine—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00196	0.00848	CcSEcCtD
Paroxetine—CYP2C8—endometrium—polycystic ovary syndrome	0.00195	0.0248	CbGeAlD
Paroxetine—HTR2A—embryo—polycystic ovary syndrome	0.00195	0.0248	CbGeAlD
Paroxetine—Hypertension—Metformin—polycystic ovary syndrome	0.00192	0.00833	CcSEcCtD
Paroxetine—SLC6A2—adrenal gland—polycystic ovary syndrome	0.00192	0.0244	CbGeAlD
Paroxetine—Myalgia—Metformin—polycystic ovary syndrome	0.00189	0.00822	CcSEcCtD
Paroxetine—Chest pain—Metformin—polycystic ovary syndrome	0.00189	0.00822	CcSEcCtD
Paroxetine—SLC6A4—endocrine gland—polycystic ovary syndrome	0.00189	0.024	CbGeAlD
Paroxetine—CHRM1—endocrine gland—polycystic ovary syndrome	0.00188	0.0239	CbGeAlD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00188	0.00816	CcSEcCtD
Paroxetine—Discomfort—Metformin—polycystic ovary syndrome	0.00187	0.00812	CcSEcCtD
Paroxetine—Oedema—Metformin—polycystic ovary syndrome	0.00182	0.00788	CcSEcCtD
Paroxetine—CHRM3—female gonad—polycystic ovary syndrome	0.00181	0.023	CbGeAlD
Paroxetine—Infection—Metformin—polycystic ovary syndrome	0.0018	0.00782	CcSEcCtD
Paroxetine—Shock—Metformin—polycystic ovary syndrome	0.00179	0.00775	CcSEcCtD
Paroxetine—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00178	0.00772	CcSEcCtD
Paroxetine—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.00178	0.00771	CcSEcCtD
Paroxetine—Skin disorder—Metformin—polycystic ovary syndrome	0.00176	0.00765	CcSEcCtD
Paroxetine—CYP2C8—pituitary gland—polycystic ovary syndrome	0.00176	0.0224	CbGeAlD
Paroxetine—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00176	0.00761	CcSEcCtD
Paroxetine—Hypotension—Metformin—polycystic ovary syndrome	0.0017	0.00736	CcSEcCtD
Paroxetine—CHRM3—endocrine gland—polycystic ovary syndrome	0.00168	0.0214	CbGeAlD
Paroxetine—SLC6A2—endocrine gland—polycystic ovary syndrome	0.00166	0.0211	CbGeAlD
Paroxetine—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00165	0.00718	CcSEcCtD
Paroxetine—Paraesthesia—Metformin—polycystic ovary syndrome	0.00163	0.00707	CcSEcCtD
Paroxetine—Dyspnoea—Metformin—polycystic ovary syndrome	0.00162	0.00702	CcSEcCtD
Paroxetine—Somnolence—Metformin—polycystic ovary syndrome	0.00161	0.007	CcSEcCtD
Paroxetine—Dyspepsia—Metformin—polycystic ovary syndrome	0.0016	0.00693	CcSEcCtD
Paroxetine—Decreased appetite—Metformin—polycystic ovary syndrome	0.00158	0.00685	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00157	0.0068	CcSEcCtD
Paroxetine—Fatigue—Metformin—polycystic ovary syndrome	0.00157	0.00679	CcSEcCtD
Paroxetine—Constipation—Metformin—polycystic ovary syndrome	0.00155	0.00674	CcSEcCtD
Paroxetine—Feeling abnormal—Metformin—polycystic ovary syndrome	0.0015	0.00649	CcSEcCtD
Paroxetine—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00149	0.00644	CcSEcCtD
Paroxetine—CYP2C8—vagina—polycystic ovary syndrome	0.00146	0.0186	CbGeAlD
Paroxetine—Urticaria—Metformin—polycystic ovary syndrome	0.00144	0.00626	CcSEcCtD
Paroxetine—Abdominal pain—Metformin—polycystic ovary syndrome	0.00144	0.00623	CcSEcCtD
Paroxetine—CYP2B6—adrenal gland—polycystic ovary syndrome	0.00141	0.018	CbGeAlD
Paroxetine—CYP2C8—endocrine gland—polycystic ovary syndrome	0.00137	0.0174	CbGeAlD
Paroxetine—CYP2B6—vagina—polycystic ovary syndrome	0.00131	0.0167	CbGeAlD
Paroxetine—Asthenia—Metformin—polycystic ovary syndrome	0.0013	0.00565	CcSEcCtD
Paroxetine—HTR2A—pituitary gland—polycystic ovary syndrome	0.00129	0.0164	CbGeAlD
Paroxetine—Pruritus—Metformin—polycystic ovary syndrome	0.00128	0.00557	CcSEcCtD
Paroxetine—ABCB1—embryo—polycystic ovary syndrome	0.00128	0.0162	CbGeAlD
Paroxetine—Diarrhoea—Metformin—polycystic ovary syndrome	0.00124	0.00539	CcSEcCtD
Paroxetine—CYP2B6—endocrine gland—polycystic ovary syndrome	0.00123	0.0156	CbGeAlD
Paroxetine—CYP2C9—endocrine gland—polycystic ovary syndrome	0.00121	0.0154	CbGeAlD
Paroxetine—Dizziness—Metformin—polycystic ovary syndrome	0.0012	0.00521	CcSEcCtD
Paroxetine—Vomiting—Metformin—polycystic ovary syndrome	0.00115	0.00501	CcSEcCtD
Paroxetine—HTR2A—adrenal gland—polycystic ovary syndrome	0.00115	0.0147	CbGeAlD
Paroxetine—Rash—Metformin—polycystic ovary syndrome	0.00115	0.00497	CcSEcCtD
Paroxetine—Dermatitis—Metformin—polycystic ovary syndrome	0.00114	0.00496	CcSEcCtD
Paroxetine—Headache—Metformin—polycystic ovary syndrome	0.00114	0.00493	CcSEcCtD
Paroxetine—Nausea—Metformin—polycystic ovary syndrome	0.00108	0.00468	CcSEcCtD
Paroxetine—HTR2A—vagina—polycystic ovary syndrome	0.00107	0.0136	CbGeAlD
Paroxetine—ABCB1—adrenal cortex—polycystic ovary syndrome	0.00105	0.0133	CbGeAlD
Paroxetine—HTR2A—endocrine gland—polycystic ovary syndrome	0.001	0.0127	CbGeAlD
Paroxetine—CYP2D6—female gonad—polycystic ovary syndrome	0.000979	0.0125	CbGeAlD
Paroxetine—ABCB1—endometrium—polycystic ovary syndrome	0.000934	0.0119	CbGeAlD
Paroxetine—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000911	0.0116	CbGeAlD
Paroxetine—ABCB1—uterus—polycystic ovary syndrome	0.000861	0.0109	CbGeAlD
Paroxetine—ABCB1—pituitary gland—polycystic ovary syndrome	0.000846	0.0108	CbGeAlD
Paroxetine—ABCB1—adipose tissue—polycystic ovary syndrome	0.000842	0.0107	CbGeAlD
Paroxetine—ABCB1—adrenal gland—polycystic ovary syndrome	0.000755	0.00961	CbGeAlD
Paroxetine—ABCB1—female gonad—polycystic ovary syndrome	0.000704	0.00896	CbGeAlD
Paroxetine—ABCB1—vagina—polycystic ovary syndrome	0.0007	0.0089	CbGeAlD
Paroxetine—ABCB1—endocrine gland—polycystic ovary syndrome	0.000655	0.00833	CbGeAlD
Paroxetine—CHRM1—Signaling Pathways—INSR—polycystic ovary syndrome	6.43e-05	9.3e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	6.42e-05	9.29e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—INSR—polycystic ovary syndrome	6.41e-05	9.27e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—INSR—polycystic ovary syndrome	6.34e-05	9.18e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—LHB—polycystic ovary syndrome	6.34e-05	9.17e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—SULT2A1—polycystic ovary syndrome	6.34e-05	9.17e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GNAS—polycystic ovary syndrome	6.3e-05	9.12e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKR1C3—polycystic ovary syndrome	6.26e-05	9.06e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—TH—polycystic ovary syndrome	6.2e-05	8.98e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	6.19e-05	8.97e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CYP17A1—polycystic ovary syndrome	6.16e-05	8.92e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	6.14e-05	8.89e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—RRM2—polycystic ovary syndrome	6.14e-05	8.88e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	6.11e-05	8.84e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKR1C3—polycystic ovary syndrome	6.09e-05	8.81e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	6.08e-05	8.81e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	6.04e-05	8.75e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—SLC2A4—polycystic ovary syndrome	6.03e-05	8.73e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GNAS—polycystic ovary syndrome	6.03e-05	8.73e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	6.03e-05	8.72e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	6.01e-05	8.7e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	6e-05	8.68e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NCOR1—polycystic ovary syndrome	6e-05	8.68e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TNRC6B—polycystic ovary syndrome	5.99e-05	8.67e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PGR—polycystic ovary syndrome	5.98e-05	8.66e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	5.97e-05	8.65e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PGR—polycystic ovary syndrome	5.95e-05	8.61e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	5.93e-05	8.59e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PGR—polycystic ovary syndrome	5.93e-05	8.59e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—LHB—polycystic ovary syndrome	5.92e-05	8.57e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—YAP1—polycystic ovary syndrome	5.92e-05	8.56e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NRG1—polycystic ovary syndrome	5.89e-05	8.52e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PGR—polycystic ovary syndrome	5.87e-05	8.5e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	5.84e-05	8.45e-05	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.8e-05	8.4e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	5.79e-05	8.38e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.74e-05	8.32e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—NAMPT—polycystic ovary syndrome	5.68e-05	8.23e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CYP19A1—polycystic ovary syndrome	5.67e-05	8.21e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	5.65e-05	8.18e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	5.65e-05	8.18e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NRG1—polycystic ovary syndrome	5.64e-05	8.16e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYP11A1—polycystic ovary syndrome	5.61e-05	8.13e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	5.6e-05	8.11e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	5.57e-05	8.07e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GHRL—polycystic ovary syndrome	5.56e-05	8.05e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PLAT—polycystic ovary syndrome	5.56e-05	8.05e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PLAT—polycystic ovary syndrome	5.53e-05	8.01e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GHRL—polycystic ovary syndrome	5.53e-05	8.01e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	5.52e-05	7.99e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GHRL—polycystic ovary syndrome	5.51e-05	7.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PLAT—polycystic ovary syndrome	5.51e-05	7.98e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GHRL—polycystic ovary syndrome	5.46e-05	7.9e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PLAT—polycystic ovary syndrome	5.46e-05	7.9e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	5.36e-05	7.76e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	5.35e-05	7.74e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—TH—polycystic ovary syndrome	5.33e-05	7.72e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—POMC—polycystic ovary syndrome	5.33e-05	7.71e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—POMC—polycystic ovary syndrome	5.31e-05	7.69e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ATF1—polycystic ovary syndrome	5.31e-05	7.68e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKR1C3—polycystic ovary syndrome	5.3e-05	7.67e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ATF1—polycystic ovary syndrome	5.28e-05	7.64e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—POMC—polycystic ovary syndrome	5.26e-05	7.62e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ATF1—polycystic ovary syndrome	5.26e-05	7.61e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYP17A1—polycystic ovary syndrome	5.22e-05	7.55e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ATF1—polycystic ovary syndrome	5.21e-05	7.54e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	5.2e-05	7.53e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—SLC2A4—polycystic ovary syndrome	5.19e-05	7.51e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	5.17e-05	7.49e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	5.16e-05	7.47e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	5.15e-05	7.46e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	5.15e-05	7.45e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	5.15e-05	7.45e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TCF7L2—polycystic ovary syndrome	5.13e-05	7.43e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	5.12e-05	7.41e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT2—polycystic ovary syndrome	5.11e-05	7.39e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	5.08e-05	7.35e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GNAS—polycystic ovary syndrome	5.06e-05	7.33e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	5.06e-05	7.32e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IRS2—polycystic ovary syndrome	5.04e-05	7.3e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	5.04e-05	7.29e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	5e-05	7.23e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	4.95e-05	7.17e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—LEP—polycystic ovary syndrome	4.94e-05	7.14e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NGFR—polycystic ovary syndrome	4.9e-05	7.09e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	4.89e-05	7.08e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CYP19A1—polycystic ovary syndrome	4.88e-05	7.06e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NGFR—polycystic ovary syndrome	4.87e-05	7.05e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—POMC—polycystic ovary syndrome	4.87e-05	7.04e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	4.86e-05	7.03e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NGFR—polycystic ovary syndrome	4.85e-05	7.03e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PRL—polycystic ovary syndrome	4.85e-05	7.02e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—POMC—polycystic ovary syndrome	4.84e-05	7.01e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IRS2—polycystic ovary syndrome	4.83e-05	6.99e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PRL—polycystic ovary syndrome	4.83e-05	6.99e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—POMC—polycystic ovary syndrome	4.82e-05	6.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—NCOR1—polycystic ovary syndrome	4.82e-05	6.98e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	4.82e-05	6.97e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PRL—polycystic ovary syndrome	4.81e-05	6.96e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NGFR—polycystic ovary syndrome	4.81e-05	6.96e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—POMC—polycystic ovary syndrome	4.78e-05	6.92e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PRL—polycystic ovary syndrome	4.76e-05	6.9e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—LEP—polycystic ovary syndrome	4.73e-05	6.84e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.68e-05	6.77e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	4.67e-05	6.76e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.65e-05	6.73e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.64e-05	6.71e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	4.63e-05	6.7e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	4.62e-05	6.69e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	4.61e-05	6.67e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.6e-05	6.66e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	4.6e-05	6.66e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.59e-05	6.65e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.58e-05	6.63e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CYP1A1—polycystic ovary syndrome	4.57e-05	6.62e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	4.57e-05	6.61e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.56e-05	6.61e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	4.55e-05	6.58e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	4.54e-05	6.57e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.52e-05	6.54e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—TH—polycystic ovary syndrome	4.52e-05	6.54e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IRS1—polycystic ovary syndrome	4.4e-05	6.37e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—SLC2A4—polycystic ovary syndrome	4.39e-05	6.36e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GNAS—polycystic ovary syndrome	4.35e-05	6.3e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	4.35e-05	6.3e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	4.31e-05	6.25e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	4.28e-05	6.2e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GNAS—polycystic ovary syndrome	4.27e-05	6.18e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—MTHFR—polycystic ovary syndrome	4.26e-05	6.17e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	4.25e-05	6.15e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GNAS—polycystic ovary syndrome	4.25e-05	6.15e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—POMC—polycystic ovary syndrome	4.24e-05	6.14e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GNAS—polycystic ovary syndrome	4.23e-05	6.13e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IRS1—polycystic ovary syndrome	4.22e-05	6.1e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—INS—polycystic ovary syndrome	4.22e-05	6.1e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GNAS—polycystic ovary syndrome	4.19e-05	6.07e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—NCOR1—polycystic ovary syndrome	4.15e-05	6e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYP19A1—polycystic ovary syndrome	4.13e-05	5.98e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IGF1—polycystic ovary syndrome	4.08e-05	5.9e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT2—polycystic ovary syndrome	4.08e-05	5.9e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.07e-05	5.89e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—POMC—polycystic ovary syndrome	4.06e-05	5.88e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.04e-05	5.85e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—INS—polycystic ovary syndrome	4.04e-05	5.84e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.03e-05	5.84e-05	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—IL6—polycystic ovary syndrome	4.01e-05	5.81e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.99e-05	5.78e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NRG1—polycystic ovary syndrome	3.99e-05	5.78e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NRG1—polycystic ovary syndrome	3.97e-05	5.75e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NRG1—polycystic ovary syndrome	3.96e-05	5.73e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TH—polycystic ovary syndrome	3.93e-05	5.69e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CYP1A1—polycystic ovary syndrome	3.93e-05	5.69e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NRG1—polycystic ovary syndrome	3.92e-05	5.67e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IGF1—polycystic ovary syndrome	3.91e-05	5.65e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT2—polycystic ovary syndrome	3.9e-05	5.65e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.87e-05	5.61e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	3.83e-05	5.54e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.71e-05	5.37e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TH—polycystic ovary syndrome	3.71e-05	5.37e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GNAS—polycystic ovary syndrome	3.69e-05	5.34e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TH—polycystic ovary syndrome	3.68e-05	5.32e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—MTHFR—polycystic ovary syndrome	3.67e-05	5.31e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	3.61e-05	5.22e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	3.6e-05	5.21e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	3.58e-05	5.18e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—NCOR1—polycystic ovary syndrome	3.51e-05	5.08e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PPARG—polycystic ovary syndrome	3.46e-05	5e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	3.42e-05	4.95e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—POMC—polycystic ovary syndrome	3.41e-05	4.93e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IRS2—polycystic ovary syndrome	3.4e-05	4.92e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	3.39e-05	4.91e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IRS2—polycystic ovary syndrome	3.39e-05	4.91e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—INS—polycystic ovary syndrome	3.39e-05	4.91e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	3.36e-05	4.87e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IRS2—polycystic ovary syndrome	3.36e-05	4.86e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	3.35e-05	4.84e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYP1A1—polycystic ovary syndrome	3.33e-05	4.82e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—LEP—polycystic ovary syndrome	3.33e-05	4.82e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—LEP—polycystic ovary syndrome	3.32e-05	4.8e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—LEP—polycystic ovary syndrome	3.28e-05	4.76e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	3.21e-05	4.65e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL6—polycystic ovary syndrome	3.12e-05	4.51e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MTHFR—polycystic ovary syndrome	3.1e-05	4.49e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	3.06e-05	4.43e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	3.03e-05	4.38e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	3e-05	4.34e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL6—polycystic ovary syndrome	2.99e-05	4.32e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.98e-05	4.32e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PPARG—polycystic ovary syndrome	2.97e-05	4.3e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.97e-05	4.3e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IRS1—polycystic ovary syndrome	2.96e-05	4.28e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—POMC—polycystic ovary syndrome	2.93e-05	4.24e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.93e-05	4.24e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—INS—polycystic ovary syndrome	2.92e-05	4.22e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	2.9e-05	4.2e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	2.88e-05	4.17e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	2.87e-05	4.16e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—POMC—polycystic ovary syndrome	2.86e-05	4.14e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	2.86e-05	4.14e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	2.86e-05	4.14e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—POMC—polycystic ovary syndrome	2.85e-05	4.13e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—INS—polycystic ovary syndrome	2.84e-05	4.12e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—INS—polycystic ovary syndrome	2.83e-05	4.1e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—POMC—polycystic ovary syndrome	2.82e-05	4.09e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—INS—polycystic ovary syndrome	2.81e-05	4.06e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.76e-05	4e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.76e-05	4e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.75e-05	3.98e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.75e-05	3.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF1—polycystic ovary syndrome	2.74e-05	3.97e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT2—polycystic ovary syndrome	2.74e-05	3.97e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	2.73e-05	3.96e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.71e-05	3.93e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.71e-05	3.93e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	2.71e-05	3.92e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	2.7e-05	3.91e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.66e-05	3.86e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.63e-05	3.8e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.61e-05	3.78e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.6e-05	3.77e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.58e-05	3.73e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.55e-05	3.69e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	2.55e-05	3.69e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	2.53e-05	3.66e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPARG—polycystic ovary syndrome	2.52e-05	3.64e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—POMC—polycystic ovary syndrome	2.48e-05	3.59e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—INS—polycystic ovary syndrome	2.47e-05	3.57e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	2.19e-05	3.17e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—POMC—polycystic ovary syndrome	2.16e-05	3.13e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—INS—polycystic ovary syndrome	2.15e-05	3.11e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.11e-05	3.06e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—polycystic ovary syndrome	2.1e-05	3.04e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—polycystic ovary syndrome	2.1e-05	3.03e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—polycystic ovary syndrome	2.08e-05	3e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	2.07e-05	2.99e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	2.05e-05	2.97e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	2.04e-05	2.95e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—INS—polycystic ovary syndrome	2.03e-05	2.93e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	2.02e-05	2.92e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—INS—polycystic ovary syndrome	2.01e-05	2.91e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—polycystic ovary syndrome	1.84e-05	2.67e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.81e-05	2.61e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.8e-05	2.6e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.79e-05	2.59e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.77e-05	2.57e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—polycystic ovary syndrome	1.76e-05	2.55e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.25e-05	1.81e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—polycystic ovary syndrome	1.24e-05	1.8e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—polycystic ovary syndrome	1.24e-05	1.79e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—polycystic ovary syndrome	1.23e-05	1.78e-05	CbGpPWpGaD
